Better Therapeutics, Inc. BTTX
0.00
0.00
NaN
as of 25 Sep
- Market cap
- $850.0K
- P/E
- 0.0×
Follow BTTX
| Older periods | Dec '22 | Mar '23 | Jun '23 | Sep '23 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(221.99%) | (448.56%) | (1,021.64%) | 2,351.81% | |
| (107.60%) | (148.61%) | (152.41%) | (162.15%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(783.76%) | 778.67% | 585.80% | 575.00% | |
Free Cash Flow per Share |
(1.28) | (1.28) | (0.93) | (0.71) | |
Free Cash Flow |
(30.11) | (30.45) | (28.91) | (27.40) | |
Capital Expenditures |
(1.18) | (1.66) | (1.76) | (1.32) | |
Piotroski F-Score |
1.00 | 1.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(97.34%) | (267.20%) | (282.25%) | (237.81%) | |
Accounts Payable Turnover |
1.20 | 1.74 | 1.46 | 1.75 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
405.93 | 325.15 | 367.21 | 270.53 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.73 | 0.73 | 0.73 | 0.83 | |
Depreciation/Fixed assets |
22.55 | 21.53 | 25.80 | 30.53 | |
Capex/Depreciation |
(0.43) | (0.59) | (0.59) | (0.42) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.23) | (1.21) | (0.87) | (0.68) | |
Capex per Share |
(0.05) | (0.07) | (0.06) | (0.03) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates